KZIA · NASDAQ

Kazia Therapeutics (KZIA) Stock Price & Fundamentals

$764.96+1.45%+$10.96End-of-day price as of Oct 9, 2026

Sample prices

Prices on this page are generated sample data for development, not real market data, so market cap, P/E and dividend yield are illustrative too. Fundamentals are real, from Kazia Therapeutics's SEC filings.

Kazia Therapeutics (KZIA) closed at $764.96 on Oct 9, 2026, up 1.45% from the previous close of $754.00.

Share price, past year

1Y +21.01%

Daily closing prices

52-week range $621.84 – $764.96.

Monthly closing prices

Last closing price of each month
Date	Close
Oct 9, 2026	$764.96
Sep 30, 2026	$743.93
Aug 31, 2026	$704.62
Jul 31, 2026	$680.53
Jun 30, 2026	$693.58
May 29, 2026	$711.34
Apr 30, 2026	$714.44
Mar 31, 2026	$740.06
Feb 27, 2026	$655.83
Jan 30, 2026	$656.98
Dec 31, 2025	$637.64
Nov 28, 2025	$668.91
Oct 31, 2025	$643.24

Key statistics

Market cap: —
P/E (TTM): —
EPS (TTM): —
Revenue (TTM): —
Net income (TTM): —
Shares outstanding: 809.4M
Dividend yield: —
52-week range: $621.84 – $764.96

Market cap, P/E and dividend yield aren't shown for Kazia Therapeutics yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in Australian dollars.

Financials

Kazia Therapeutics reported revenue of A$42.00K for fiscal 2025, down 98.18% from fiscal 2024.

Figures are in Australian dollars (AUD), as Kazia Therapeutics reports them to the SEC.

Kazia Therapeutics reported a net loss of A$20.70M in fiscal 2025.

Annual revenue

FY16FY17FY18FY21FY22FY23FY24FY25

Kazia Therapeutics annual financials by fiscal year, from SEC filings
Fiscal year	Revenue	Growth	Net income	Net margin	EPS (diluted)	Free cash flow
FY2025ended Jun 30, 2025	A$42.00K	−98.2%	−A$20.70M	−49,290.5%	−A$0.0378	—
FY2024ended Jun 30, 2024	A$2.31M	—	−A$26.78M	−1,160.2%	−A$0.1016	—
FY2023ended Jun 30, 2023	A$0.00	—	−A$20.47M	—	−A$0.1123	—
FY2022ended Jun 30, 2022	A$0.00	−100.0%	−A$25.01M	—	−A$0.1888	—
FY2021ended Jun 30, 2021	A$15.18M	+12,658.8%	−A$8.42M	−55.5%	−A$0.0716	—
FY2018ended Jun 30, 2018	A$119.00K	−52.2%	−A$6.04M	−5,074.8%	−A$12.48	—
FY2017ended Jun 30, 2017	A$249.00K	−38.7%	−A$10.67M	−4,285.1%	−A$2.28	−A$11.45M
FY2016ended Jun 30, 2016	A$406.00K	—	−A$12.06M	−2,971.2%	−A$2.82	−A$12.50M

Company profile

Name: Kazia Therapeutics Limited
Ticker: KZIA
Exchange: NASDAQ
Industry (SEC SIC): Pharmaceutical Preparations
Headquarters: Three International Towers Level 24,, 300 Barangaroo Avenue, Sydney Nsw, 2000
Incorporated in: C3
Fiscal year ends: June
SEC CIK: 0001075880

Recent SEC filings

20-FAnnual report for period ending Jun 30, 2025
Nov 7, 2025
20-FAnnual report for period ending Jun 30, 2024
Nov 15, 2024
20-FAnnual report for period ending Jun 30, 2023
Oct 26, 2023
20-FAnnual report for period ending Jun 30, 2022
Oct 17, 2022
20-FAnnual report for period ending Jun 30, 2021
Oct 7, 2021
20-FAnnual report for period ending Jun 30, 2020
Oct 22, 2020
20-FAnnual report for period ending Jun 30, 2019
Oct 21, 2019
20-FAnnual report for period ending Jun 30, 2018
Oct 24, 2018

Frequently asked questions

What is Kazia Therapeutics's stock price?

Kazia Therapeutics (KZIA) closed at $764.96 on Oct 9, 2026, up 1.45% from the previous close of $754.00.

How much revenue does Kazia Therapeutics make?

Kazia Therapeutics reported revenue of A$42.00K for fiscal 2025, down 98.18% from fiscal 2024.

Sources and methodology

Fundamentals come from Kazia Therapeutics Limited's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures